DMEMEDS shared post via Reuters: AstraZeneca suffers setback as drug fails in eye cancer

LONDON (Reuters) - AstraZeneca's much anticipated cancer drug pipeline suffered a modest blow on Wednesday when the experimental drug selumetinib failed to meet its goal in a late-stage trial for a rare cancer of the eye. [Category: healthNews] http://feeds.reuters.com/~r/reuters/healthNews/~3/D1o8CnqxgIg/story01.htm

Read More